Drug Details

General Information of the Drug (ID: DR1895)
Name
Losartan
Synonyms
losartan; 114798-26-4; DUP 89; Lortaan; Cozaar; LOSARTAN POTASSIUM; Hyzaar; UNII-JMS50MPO89; CHEBI:6541; MK-954; JMS50MPO89; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; DTXSID7023227; DuP 753; MFCD00865831; [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; NCGC00095125-01; Losartan [INN:BAN]; DSSTox_CID_3227; DSSTox_RID_76933; DSSTox_GSID_23227; (1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol; (1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol; [2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl)methyl)-; 1H-imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; C22H23ClN6O; (1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol; [3H]losartan; Losartan (INN); Losartic (TN); 2-BUTYL-4-CHLORO-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-IMIDAZOLE-5-METHANOL; [3H]-losartan; CAS-114798-26-4; SR-01000763170; lorastan; 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol; [2-butyl-5-chloro-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; Losartan-[d3]; PubChem9176; Dup89; Spectrum_001713; SCHEMBL60; Spectrum2_001677; Spectrum3_000998; Spectrum4_001126; Spectrum5_001466; Epitope ID:140137; EC 601-329-8; Oprea1_644635; US9624243, Losartin; BSPBio_002695; GTPL590; KBioGR_001611; KBioSS_002193; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol; BIDD:GT0286; SPECTRUM1504268; SPBio_001893; DUP-89; GTPL3941; BDBM82258; HSDB 7043; KBio2_002193; KBio2_004761; KBio2_007329; KBio3_001915; HGP1405; BCPP000183; BDBM318822; EX 89; HMS1922J13; HMS2093E22; HMS3715L11; Pharmakon1600-01504268; BCP27731; HGP-1405; NSC_3961; ZINC3873160; Tox21_111435; CCG-39095; NSC758699; s5067; STL419984; 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol; AKOS015917390; AKOS015994740; Tox21_111435_1; AB07507; BCP9000861; DB00678; KS-5004; MCULE-5204931675; NSC 758699; NSC-758699; (2-butyl-4-chloro-1-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole; NCGC00095125-02; NCGC00095125-03; NCGC00095125-05; NCGC00095125-08; [2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol; 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol; AK326126; HY-17512; I497; SBI-0206766.P001; AB0013723; CAS_114798-26-4; FT-0631074; C07072; D08146; 54244-EP2269989A1; 54244-EP2270011A1; 54244-EP2272841A1; 54244-EP2277879A1; 54244-EP2287165A2; 54244-EP2287166A2; 54244-EP2292620A2; 54244-EP2295053A1; 54244-EP2295406A1; 54244-EP2298772A1; 54244-EP2298776A1; 54244-EP2298779A1; 54244-EP2301923A1; 54244-EP2301931A1; 54244-EP2301936A1; 54244-EP2305219A1; 54244-EP2308562A2; 54244-EP2308839A1; AB01563296_01; 798L264; A803239; L000351; Q410074; Q-201321; SR-01000763170-3; SR-01000763170-4; BRD-K76205745-001-02-5; BRD-K76205745-001-04-1; F2173-0506; [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-imidazolyl]methanol; 2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)-biphenyl-4-yl)methyl]imidazole; 2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; (1-((2'-(2h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1h-imidazol-5-yl)methanol; {2-Butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-yl}-methanol; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI); 2-butyl-4-chloro-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-methanol; 2-butyl-4-chloro-1-[2'-(2H-tetrazol-5-yl)-1,1'-biphenyl-4-ylmethyl]-1H- imidazole-5-methanol; 2-butyl-4-chloro-5-(hydroxymethyl)-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole
    Click to Show/Hide
Molecular Type
Small molecule
Disease Hypertension [ICD-11: BA00] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C22H23ClN6O
PubChem CID
3961
Canonical SMILES
CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
InChI
1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
InChIKey
PSIFNNKUMBGKDQ-UHFFFAOYSA-N
CAS Number
CAS 114798-26-4
ChEBI ID
CHEBI:6541
TTD Drug ID
D0DD0K
DrugBank ID
DB00678
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Apocynin      Picrorhiza kurrooa     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model A 5/6 nephrectomy mouse model of CDK was used in this study.
                    Experimental
                    Result(s)		 Apocynin in conjunction with a coadjuvant for modulating blood pressure may be useful for controlling the progression of CRF.
          L-carnitine      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Diabetes was induced by intraperitoneal injection of streptozotocin (STZ) (60 mg/kg) in rat.
                    Experimental
                    Result(s)		 The combined therapy of losartan and L-carnitine affords additive beneficial effects against diabetes-associated endothelial dysfunction, possibly via normalizing the dysregulated eNOS and reducing the inflammation and oxidative stress in diabetic rats.
    β. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug
          Mycophenolate mofetil      Penicillium stoloniferum     Click to Show/Hide the Molecular Data of This NP
                 Decreasing Adverse Drug Reaction     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [4]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression AGTRAP  Molecule Info 
Pathway MAP
                    In-vivo Model Male Sprague-Dawley rats, weighing 225 to 250 g were used in this study.
                    Experimental
                    Result(s)		 MMF treatment decreases CsA-induced nephrotoxicity, and combined treatment with LSRT has a synergistic effect in preventing chronic CsA nephrotoxicity.
Target and Pathway
Target(s) Angiotensin II receptor type-1 (AGTR1)  Molecule Info  [5]
KEGG Pathway Calcium signaling pathway Click to Show/Hide
2 cGMP-PKG signaling pathway
3 Neuroactive ligand-receptor interaction
4 Adrenergic signaling in cardiomyocytes
5 Vascular smooth muscle contraction
6 Renin-angiotensin system
7 Renin secretion
8 Pathways in cancer
NetPath Pathway TGF_beta_Receptor Signaling Pathway Click to Show/Hide
Panther Pathway Angiotensin II-stimulated signaling through G proteins and beta-arrestin Click to Show/Hide
Pathwhiz Pathway Angiotensin Metabolism Click to Show/Hide
2 Muscle/Heart Contraction
Pathway Interaction Database Arf6 trafficking events Click to Show/Hide
2 Arf6 signaling events
3 Angiopoietin receptor Tie2-mediated signaling
Reactome Peptide ligand-binding receptors Click to Show/Hide
2 G alpha (q) signalling events
WikiPathways ACE Inhibitor Pathway Click to Show/Hide
2 GPCRs, Class A Rhodopsin-like
3 Gastrin-CREB signalling pathway via PKC and MAPK
4 Peptide GPCRs
5 Allograft Rejection
6 GPCR ligand binding
7 GPCR downstream signaling
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 590).
Reference 2 Apocynin combined with drugs as coadjuvant could be employed to prevent and/or treat the chronic kidney disease. Ren Fail. 2018 Nov;40(1):92-98.
Reference 3 Combination therapy with losartan and L-carnitine protects against endothelial dysfunction of streptozotocin-induced diabetic rats. Eur J Pharmacol. 2014 Dec 5;744:10-7.
Reference 4 Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Transplantation. 2003 Feb 15;75(3):309-15.
Reference 5 Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link